Accessibility Menu
Astria Therapeutics logo

Astria Therapeutics(NASDAQ) CATB

This security has been delisted. This page is retained for historical reference.

Astria Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 12.582026-01-22
Astria Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.8%USD 12.812026-01-15
1 month-2.48%USD 12.902025-12-23
3 month+1.13%USD 12.442025-10-24
Year to date-3.9%USD 13.092025-12-31
1 year+67.73%USD 7.502025-01-22
3 year-13.89%USD 14.612023-01-23
5 year-23.2%USD 16.382021-01-22
Since inception-98.39%USD 780.002015-06-25

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

CATB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

-15144.33%

Net Income Margin

-13938.24%

Return on Equity

-37.70%

Return on Capital

-34.37%

Return on Assets

-36.20%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$106.92M

EBITDA

-$104.46M

Operating Cash Flow

-$102.37M

Capital Expenditure

-$590.00K

Free Cash Flow

-$102.96M

Cash & ST Invst.

$227.72M

Total Debt

$4.46M

Astria Therapeutics Performance Analysis

Astria Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Astria Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Astria Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -24.58N/A
20222022-12-31USD -3.55-85.6%
20232023-12-31USD -2.42-31.7%
20242024-12-31USD -1.68-30.6%
Astria Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-301.7%
Q32025-09-303.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$706.00K

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

20

N/A

Net Income

-$31.64M

N/A

EBITDA

-$31.64M

N/A

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$227.72M

N/A

Total Debt

$4.46M

N/A

Accounts Receivable

$17.24M

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.06M

N/A

Short Term Debt

$1.40M

N/A

Return on Assets

-36.20%

N/A

Return on Invested Capital

-43.05%

N/A

Free Cash Flow

-$32.30M

N/A

Operating Cash Flow

-$32.30M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRNAcelyrin, Inc.
$2.27+0.00%
CELUCelularity Inc.
$0.72+1.72%
THRDThird Harmonic Bio, Inc.
$5.38-0.09%
MACKMerrimack Pharmaceuticals, Inc.
$15.15+0.10%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$109.67-0.12%
NVDANvidia
$220.94+0.04%
ONDSOndas
$8.90+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.83-0.03%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.